Rising drug allergy alert overrides in electronic health records : an observational retrospective study of a decade of experience. by Topaz,  M. et al.
Durham Research Online
Deposited in DRO:
01 July 2016
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Topaz, M. and Seger, D.L. and Slight, S.P. and Goss, F. and Lai, K. and Wickner, P.G. and Blumenthal, K.
and Dhopeshwarkar, N. and Chang, F. and Bates, D.W. and Zhou, L. (2016) 'Rising drug allergy alert
overrides in electronic health records : an observational retrospective study of a decade of experience.', Journal
of the American Medical Informatics Association., 23 (3). pp. 601-608.
Further information on publisher's website:
http://dx.doi.org/10.1093/jamia/ocv143
Publisher's copyright statement:
This is a pre-copyedited, author-produced PDF of an article accepted for publication in Journal of the American
Medical Informatics Association following peer review. The version of record Topaz, M., Seger, D.L., Slight, S.P., Goss,
F., Lai, K., Wickner, P.G., Blumenthal, K., Dhopeshwarkar, N., Chang, F., Bates, D.W. Zhou, L. (2016). Rising drug
allergy alert overrides in electronic health records: an observational retrospective study of a decade of experience.
Journal of the American Medical Informatics Association 23(3): 601-608 is available online at:
http://dx.doi.org/10.1093/jamia/ocv143.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
1 
 
Rising drug allergy alert overrides in electronic health records: an observational 
retrospective study of a decade of experience. 
Authors: Maxim Topaz PhD, RN
 a,b
, Diane L Seger RPh
a,c
, Sarah P. Slight PhD, PGDip
a,d
, 
Foster Goss DO
e
, Kenneth Lai MA
a
, Paige G Wickner MD
a
, Kimberly Blumenthal MD
b,f
, 
Neil Dhopeshwarkar BS
a
, Frank Chang MSc
a
, David W. Bates MD, MSc
a,b
, Li Zhou MD, 
PhD
 a,b,c 
a 
Division of General Internal Medicine & Primary Care, Brigham and Women's Hospital, 
Boston, MA, USA 
b
 Harvard Medical School, Boston, MA, USA 
c 
Clinical & Quality Analysis , Partners Healthcare System, Wellesley, MA, USA
 
d 
Division of Pharmacy, School of Medicines, Pharmacy and Health, Durham University, 
Durham, U.K. 
e 
Department of Emergency Medicine, University of Colorado, Aurora, CO, USA 
f 
Division of Rheumatology, Allergy and Immunology, and Medical Practice Evaluation Center, 
Department of Medicine, Massachusetts General Hospital, Boston MA 
Corresponding author:  
Maxim Topaz PhD, RN, MA 
93 Worcester st., Wellesley Gateway, Suite 2030I 
Wellesley, MA, 02481 USA 
Phone: 781-416-8525 
Email: mtopaz80@gmail.com  
Word count: 3,012 words 
Key words: Allergy; Electronic Health Records; Electronic Prescribing; Decision Support 
Systems–Clinical; Alert Fatigue; Medication Systems, Hospital 
Funding: This study was funded by the Agency for Healthcare Research and Quality (AHRQ) 
grant (1R01HS022728-01).  
2 
 
Abstract:  
Objective: There have been growing concerns about the impact of drug allergy alerts on patient 
safety and provider alert fatigue. We aimed to explore the common drug allergy alerts over the 
last ten years and the reasons why providers tend to override these alerts.  
Design: Retrospective observational cross-sectional study (2004-2013).  
Materials and Methods: Drug allergy alert data (n= 611,192) were collected from two large 
academic hospitals in Boston, MA (USA).  
Results: Overall, we found an increase in the rate of drug allergy alert overrides, from 83.3% in 
2004 to 87.6% in 2013 (p<.001). Alarmingly, alerts for immune mediated and life threatening 
reactions with definite allergen and prescribed medication matches were overridden 72.8% and 
74.1% of the time, respectively. However, providers were less likely to override these alerts 
compared to possible (cross-sensitivity) or probable (allergen group) matches (p<.001). The most 
common drug allergy alerts were triggered by allergies to narcotics (48%) and other analgesics 
(6%), antibiotics (10%) and statins (2%). Only slightly more than one-third of the reactions 
(34.2%) were potentially immune mediated. Finally, more than half of the overrides reasons 
pointed to irrelevant alerts (i.e. Patient has tolerated the medication before, 50.9%) and providers 
were significantly more likely to override repeated alerts (89.7%) rather than first time alerts 
(77.4%, p<.001).  
Discussion and Conclusions: Our findings underline the urgent need for more efforts to provide 
more accurate and relevant drug allergy alerts to help reduce alert override rates and improve 
alert fatigue. 
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INTRODUCTION 
Health information technology can play a key role in how we currently diagnose, treat 
and monitor patients. Electronic health records with computerized provider order entry systems 
can provide the clinician with real-time guidance and support at the point of prescribing.[1] 
These systems have been shown to improve the safety and quality of patient care by, for 
example, reducing the likelihood of medication errors and consequent patient harm.[2] One of 
the basic drug interaction alert types is a drug allergy checking. This provides the clinicians with 
an alert or reminder if the patient has a documented allergy in their electronic health record to the 
prescribed drug. However, clinicians can be exposed to a high number of drug allergy alerts, 
which can result in them experiencing alert fatigue; clinicians can often ignore or override both 
clinically important and unimportant alerts.[3, 4] Ignoring alerts can potentially lead to patient 
harm and other unintended consequences, thus many efforts are underway to improve the 
accuracy of the alerts and reduce clinicians’ alert fatigue.[5, 6] Unfortunately, little is known 
about the acceptance rates and other aspects of drug allergy alerts presented to providers.  
Several factors can potentially affect the providers’ tendency to override the drug allergy 
alerts, for example the nature of the reaction associated with the alert. True immune mediated 
reactions are rare and can result in hives, severe hypotension, and anaphylaxis.[7] Non-immune 
mediated reactions and medication intolerances are more common and often present as 
gastrointestinal upset, nausea, and vomiting, etc.[7] It is currently unclear how often providers 
override these different types of reactions. Furthermore, drug allergy alerts may not be generated 
by an exact match between the allergy and prescribed medication (e.g. codeine--> codeine), but 
rather by a possible cross-reactivity association between medications that are chemically or 
structurally related (e.g., codeine--> oxycodone). To the best of our knowledge, no study has 
specifically looked at how often drug allergy alerts associated with these different types of 
matches are overridden and whether the quantity of alerts related to non-immune mediated 
reactions might potentially increase the risk of alert fatigue among providers.   
In this study, we aimed to: 1) evaluate providers’ drug allergy alert overrides over the last 
ten years (2004-2013); 2) examine the different types of reactions overridden (immune mediated 
vs. non-immune mediated; potentially life threatening vs. non-life threatening) and whether these 
related to definite, probable or possible drug-allergy matches; and 3) examine the reasons why 
providers chose to override these drug-allergy alerts.  
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METHODS 
In this observational, cross sectional study, we assessed ten years of drug allergy alert records 
from two large academic medical centers (Brigham and Women's Hospital and Massachusetts 
General Hospital). Both hospitals are part of Partners Healthcare, an integrated healthcare system 
in the Boston area. Data were extracted from the Partners Enterprise-wide Allergy Repository 
(PEAR), a longitudinal allergy database shared within the Partners provider/hospital network.[8] 
This study is a part of a larger study focused on creating methods for natural language processing 
of allergy information in the electronic health records (Agency for HealthCare Research and 
Quality [AHRQ] grant 1R01HS022728-01). For this larger study, a database of a decade of 
allergy alert override trends was compiled and this data served for this analysis.   
Drug allergy interaction database 
In PEAR, medications are stored and encoded using a combination of proprietary (First 
Databank, Inc.
TM
) and local (Partners Master Drug Dictionary) terminologies. For patients 
admitted to the healthcare system, providers enter patient allergy information or indicate no 
known allergies in the electronic health record. Drugs or drug groups causing allergy are entered 
as structured data while allergic reactions can be entered as structured or free text information.  
The electronic health record system checks every prescribed medication against possible 
allergies in PEAR. Drug allergy alerts are triggered when a prescribed medication matches the 
stored allergy as either:  
1. Definite match: exact match between allergen and prescribed medication (or main 
medication ingredient), i.e. levofloxacin --> levofloxacin.  
2. Probable match: prescribed medication matches allergen group of the documented 
allergen, i.e. ciprofloxacin --> levofloxacin. 
3. Possible match: the cross-sensitivity group of the patient’s allergen matches the cross-
sensitivity group of the medication ingredient, i.e. penicillin (penicillins) --> cephalexin 
(cephalosporins).  
The knowledge base has been updated over the years, with some small additions made to some 
of the match types but no major systematic changes. Drug allergy alerts present several 
informational components to the providers, including: allergen (e.g., penicillins); the prescribed 
medication (e.g., amoxicillin); allergy-prescribed medication match type (e.g., 
definite/probable/possible as explained above); and patient’s reaction(s) (e.g., anaphylaxis), if 
known.  
We downloaded all inpatient drug allergy alerts (n= 928,962) from the PEAR database between 
Jan 2004 and Dec 2013. We then concentrated on the most commonly triggered drug allergy 
alerts with frequencies higher than 0.1% of total alerts, resulting in 611,192 records (65.8%) 
which were included in this analysis. 
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When presented with a drug allergy alert, a provider can either cancel the prescribed medication 
or override the drug allergy alert. If they decide to override the alert, providers in our inpatient 
settings are asked to enter a free text override reason. See Figure 1 for a screen-shot of a drug 
allergy alert. Providers’ decisions and alert information are stored in PEAR. In our outpatient 
electronic health records, five structured override reason categories are offered to providers. 
These categories include: 1) Patient has tolerated the drug previously; 2) Patient reports no 
allergy; 3) No reasonable alternative (will monitor for reaction); 4) Patient has sensitivity but 
will be pre-medicated prior to medication administration; and 5) Other. Consistently with the 
outpatient structured reasons, we classified the inpatient free text providers’ override reasons into 
those five categories: For example, both free text override reasons 1. “Tolerated the med” and 2. 
“Previously took the medication with no side effects” were classified as “Patient has tolerated the 
drug previously”. Override reason classification was performed jointly by two study members 
(the first author and study research assistant) and reviewed by the study team for consistency and 
accuracy. Overall, there were 284,858 alert override reasons. Reasons were mostly repetitive, 
with mean override reason frequency appearance of 7.6 times and 23,231 unique reasons 
presented. All reasons were classified into one of the five abovementioned categories. Of note: at 
the time of the study, override reason information from only one of the participating sites 
(Brigham and Women’s Hospital) was available, thus the reported override reasons are based on 
this site data. 
Figure 1 (comes around here): Screen-shot of a drug allergy alert in the electronic health record.   
Reaction type classification  
Each alert warning lists one or more reactions that the patient is at risk of being exposed to, e.g., 
anaphylaxis. Our research team in collaboration with two allergy specialists (PGW and KGB), 
reviewed these different types of reactions as well as the current literature[7, 9, 10] and classified 
them into two main types: 1. Potentially immune mediated (i.e., rash or anaphylaxis) or non-
immune mediated (i.e., nausea or vomiting), and 2. Potentially life threatening (i.e. anaphylaxis 
or bronchospasm) or non-life threatening (i.e. gastrointestinal upset or nausea).  
Statistical and other procedures  
Microsoft SQL Server Management Studio[11] was used to store and manage all data including 
allergens, medication groups, and drug allergy alert override rates/reasons. We calculated the 
frequencies of drug allergy alerts and reactions for the most common medication groups that 
triggered drug allergy alerts. To generate the medication groups we used a proprietary 
vocabulary developed and maintained by a vendor serving the healthcare system (First Databank, 
Inc.). We also examined how many times each drug allergy alert was triggered. Factors 
associated with drug allergy overrides were analyzed by comparing the frequencies of life 
threatening and immune mediated allergic reactions. We also queried the PEAR database for 
allergy-medication match type (i.e., definite, probable, or possible) and then compared the 
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frequencies of drug allergy alert overrides for immune mediated and life threatening reactions by 
allergen- medication match type. Statistical procedures included t-tests and chi-square tests, 
when appropriate. The statistical analysis and group comparisons were conducted in STATA 
v.11.[12] Override reasons were explored by calculating the frequencies of the drug allergy alerts 
override reasons recorded by the providers. This study was approved by Partners Institutional 
Review Board (IRB).  
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RESULTS 
Exploring the drug allergy alerts  
Figure 2 shows the most common medication groups that triggered drug allergy alerts. The most 
common medication group was narcotics (Figure 1). Of the 611,192 drug allergy alerts, almost 
half (48%) were triggered by narcotics, 10% by antibiotics, 6% other analgesics and statins (2%) 
(Figure 1). On average, drug allergy alerts were repeated 2.3 times after the first warning.         
Figure 2 (comes around here): Medication groups associated with the most commonly triggered 
drug allergy alerts.  
 
Table 1 shows the 15 most common reactions (n=438,509, 91.2% of all 627,000 reactions) 
presented to the provider in the drug allergy alerts. Only about one third (34.2%) of all the 
reactions were potentially immune mediated while 44.5% were potentially non-immune 
mediated and 21.3% were unknown (Table 1). In addition, the majority of alerts were triggered 
by potentially non-life threatening reactions (68.2%) while only 10.5% had potentially life 
threatening reactions and the rest (21.3%) were reactions documented as “Unknown”. On 
average, drug allergy alerts examined in this study were associated with 1.03 allergic reactions.              
Table 1: Common allergic reactions associated with drug allergy alerts in inpatient settings.    
Reaction 
Reaction 
frequency* 
% 
Reaction 
out of 
total 
Potentially 
immune 
mediated 
reactions 
Potentially 
life 
threatening 
reactions 
Hives or rash 128,288 20.5 Yes No 
Gastrointestinal upset 100,074 15.9 No No 
Itching 46,596 7.4 Yes No 
Vomiting 31,520 5 No No 
Nausea 28,796 4.6 No No 
Mental status change 28,001 4.5 No Yes 
Anaphylaxis 26,716 4.3 Yes Yes 
Swelling 10,573 1.7 Yes Yes 
Shortness of breath 8,036 1.3 Yes Yes 
Angioedema 7,945 1.3 Yes Yes 
Myalgia 6,066 1 No No 
Headaches 5,889 0.9 No No 
Bronchospasm or 
wheezing 
4,709 0.8 Yes Yes 
Hypotension 3,440 0.6 Yes Yes 
Seizures 1,860 0.3 No Yes 
Other reactions (small #) 55,101 8.5 --- --- 
Unknown** 133,390 21.5 --- --- 
Total  627,000 100 214,562 65,837 
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 *The total frequency of allergic reactions is larger than unique drug allergy alerts triggered since 
each unique drug allergy alert could have more than one associated reaction. 
**A reaction entry documented by providers as ‘Unknown’ in the allergy entry section of the 
electronic health record.   
 
Most of the drug allergy alerts (74.8%, n=457,316) were triggered by a probable match while the 
rest were based on either definite (12.2%, n=74,720) or possible (13%, n=79,156) matches.    
In the analyzed common drug allergy alert subset, the override rate was 86.3%, which is slightly 
higher than the overall override rate of 83.9%. Interestingly, providers were less likely to 
override first time drug allergy alerts (77.4% overrides, n= 132,314) while repeated alerts that 
appeared two or more times were overridden more frequently (89.7%, n= 394,891, p< .001). In 
general, the rate of overrides has increased, from 83.3% in 2004 to 87.6% in 2013.  
Drug – allergy match types 
Overall, definite allergy-medication match type was overridden significantly less frequently 
(74.6%) than possible (80.7%) and probable (89.1%) match types (p<.001) (Figure 3). 
Potentially life threatening reactions were overridden slightly less frequently (83.6%) than 
unknown (85.6%) or non-life threatening (86.9%) reactions (p<.001).       
Figure 3 (comes around here): Drug allergy alert override rates by allergy-prescribed medication 
match type, immune mediated status and life threatening status reactions.  
Providers were significantly more likely to override probable matches for both life threatening 
(89.5%) and non-life threatening (87.3%) reactions whereas definite matches were overridden 
less frequently (74.1% life threatening, 75.1% non-life threatening, p<.001) (Table 2). Similar 
trends were identified in potentially immune mediated reactions. 
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Table 2: Inpatient drug allergy alert overrides by allergen-prescribed medication match types.  
Reaction type 
Allergy/ 
Medication 
match* 
Alert Overridden 
N (%)** 
Overall N 
(%)*** 
Immune 
mediated 
reactions  
 
  
Potentially non-
immune mediated 
reactions 
Definite 29233 (76.2) 38382 (6.3) 
Possible 8676 (83.1) 10444 (1.7) 
Probable 195315 (90.3) 216222 (35.4) 
Potentially 
immune mediated 
reactions 
Definite 15900 (72.8) 21827 (3.6) 
Possible 36240 (80) 45308 (7.4) 
Probable 129273 (87.7) 147427 (24.1) 
Unknown 
reactions 
Definite 10605 (73.1) 14511 (2.4) 
Possible 18961 (81) 23404 (3.8) 
Probable 83002 (88.6) 93667 (15.3) 
Life threatening 
reactions  
  
Potentially non-
life threatening 
Definite 39,221 (75.1) 52,223 (8.5) 
Possible 37,431 (82.1) 45,603 (7.5) 
Probable 281,875 (89.5) 314,781 (51.5) 
Potentially life 
threatening 
Definite 5,887 (74.1) 7,949 (1.3) 
Possible 7,259 (73.3) 9,899 (1.6) 
Probable 41,904 (87.3) 47,989 (7.9) 
Unknown  
Definite 10,630 (73.1) 14,548 (2.4) 
Possible 19,187 (81.1) 23,654 (3.9) 
Probable 83,811 (88.6) 94,546 (15.5) 
Total 
 
527,205 (86.3) 611,192 
* Possible types of allergy-medication matches: 1) Definite match: exact match between 
allergen and prescribed medication (or main medication ingredient), i.e. levofloxacin --> 
levofloxacin; 2) Probable match: prescribed medication matches allergen group of the 
documented allergen, i.e. ciprofloxacin --> levofloxacin; 3) Possible match: the cross-sensitivity 
group of the patient’s allergen matches the cross-sensitivity group of the medication ingredient, 
i.e. penicillin (penicillins) --> cephalexin (cephalosporins). 
** Percentage of alerts overridden out of total alerts for this allergy/medication match. 
*** Percentage of alerts out of total alerts. 
 
The most overridden drug allergy alerts were for statins (n=18,541, 88.3%) and narcotics 
(n=300,286, 88.7%) (Figure 4). Salicylate analgesics (e.g., aspirin) and penicillin alerts were 
overridden the least (n=16,971, 78.2% and n=49,167, 74.3%, respectively).  
Figure 4 (comes around here): Drug allergy alert override rates by allergy medication group.  
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Table 3 shows examples of the 10 most and 10 least overridden allergy-prescribed medication 
combinations. Similarly to the trends presented in Table 2, the most frequently overridden alerts 
were triggered by probable allergy-prescribed medication matches while definite matches were 
overridden less frequently.  
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Table 3: Examples of the 10 most and 10 least overridden drug allergy alerts in inpatient settings.    
Allergy Prescribed medication generic name 
Allergy-prescribed 
medication match 
# 
Override
s 
% 
Override
s*** 
Total 
alerts 
% Overall 
alerts 
10 most overridden drug allergy alerts 
Percocet Hydromorphone 0.5 mg/ml Probable  603 98.05 615 0.1 
Morphine Controlled Release Hydromorphone Hcl Probable  1857 96.82 1918 0.3 
Opioids - Morphine Analogues Hydromorphone Hcl Probable  1192 95.13 1253 0.2 
Simvastatin Rosuvastatin Probable  1093 94.71 1154 0.2 
Oxycodone 5 mg/ Acetaminophen 
325 mg 
Hydromorphone Hcl Probable  1200 94.71 1267 0.2 
Simvastatin Pravastatin Probable  1009 94.65 1066 0.2 
Oxycodone Controlled Release Hydromorphone Hcl Probable  1686 94.61 1782 0.3 
Percocet Hydromorphone Hcl Probable  15037 94.53 15907 2.6 
Atorvastatin Pravastatin Probable  1743 94.47 1845 0.3 
Ibuprofen Acetylsalicylic Acid (Aspirin) Probable  2822 92.2 3061 0.5 
10 least overridden drug allergy alerts 
Penicillins Ampicillin/Sulbactam Probable  405 48.91 828 0.1 
Meperidine  Meperidine Hcl Definite  726 48.02 1512 0.3 
Simvastatin Simvastatin Definite  313 47.86 654 0.1 
Demerol Meperidine Hcl Definite  487 47.10 1034 0.2 
NSAIDs Ibuprofen Probable  607 45.13 1345 0.2 
Penicillins Ampicillin Probable  715 42.87 1668 0.3 
Sulfa (Sulfonamide Antibiotics) Trimethoprim/ Sulfamethoxazole Double 
Strength 
Probable  249 40.69 612 0.1 
Ibuprofen Ibuprofen Definite 341 39.51 863 0.1 
Sulfa Trimethoprim/Sulfamethoxazole double 
strength 
Probable 563 39.43 1428 0.2 
Percocet Oxycodone 5 mg/ Acetaminophen 325 mg Definite 549 37.09 1480 0.2 
* HMG CoA: 3-hydroxy-3-methylglutaryl-coenzyme  
** COX: cyclooxygenase  
*** Percentage of alerts overridden out of total alerts for this allergy/medication combination.  
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Drug allergy alerts override reasons  
The most common override reason was related to whether the patient had previously tolerated 
the medication (n=145,112, 50.9%), while (n=9,930, 3.5%) reported that patients reported that 
they had no allergy (Table 4). The “other” reasons (n=88,015, 30.9%) were presented as other 
ambiguous free-text entries, such as a single letter (e.g., “a”, “D”), “pain protocol” or “OK with 
patient/ family”.  Since half of the cases were indicated as either previously tolerated or no 
existing allergy, we compared the rates of possibly life threatening reactions overrides without 
those two override groups within the hospital site where the override reasons data were available. 
Override trends (not shown) were similar to those presented in Table 2.  
Table 4: Inpatient drug allergy alerts override reasons.  
Override reason Override reason 
frequency  
% out of 
total 
override 
reasons  
Patient has tolerated the drug previously 145,112 50.9 
Patient reports no allergy  9,930 3.5 
No reasonable alternative- will monitor for reaction 37,465 13.1 
Patient has sensitivity but will be pre-medicated prior to 
administration 
3,596 1.3 
Other 88,015 30.9 
Unknown 740 0.3 
Total  284,858  
 
DISCUSSION 
The goals of this study were to identify the most common drug allergy alerts over the past 
decade and examine factors associated with providers’ tendency to override those alerts. We also 
examined the override reasons for the common drug allergy alerts, and identified areas for 
further investigation and lessons learned to potentially improve the clinical utility of the drug 
allergy alerting.    
Exploring the drug allergy alerts 
Our results suggest that, in hospital settings, almost half of the drug allergy alerts are triggered 
by medications from the narcotic analgesics group (i.e. morphine, codeine, etc.). Previous studies 
from one of the institutions analyzed here (Brigham and Women’s Hospital) present an 
interesting trend of general increase in the rate of opioid alerts over the years: between 1995-99, 
one-third (32.9%) of the alerts were for narcotics;[13] followed by 39% of alerts in 2002; [14] 
and reaching a peak of 48% in this study. Evidence from other sites indicates that narcotic 
analgesics alerts can constitute up to 69% of all drug allergy alerts.[15] This trend might be 
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partially explained by the consistent increase in the opioid drug prescription rates over time in 
inpatient and outpatient settings. For instance, several recent studies have reported that opioid 
prescriptions increased as high as three-fold in the past two decades in the US.[16-19] In 
practice, this finding underlines the critical importance of managing opioid related allergies 
information appropriately within the computerized provider order entry systems and allergy 
repositories to avoid potential over-alerting.  
Other common drug allergy alerts were triggered by antibiotics (especially penicillins), other 
analgesics and statin (HMG CoA inhibitors), responsible in total for about one-fifth of the drug 
allergy alerts. Those trends are similar to the previously reported findings with some minor 
differences.[13-15, 20] For example, we found that statins are becoming an increasingly 
prevalent trigger for drug allergy alerts (2% of all alerts) whereas previous studies found only 
minute instances of this alert. This finding is consistent with the increasing rates of statin 
prescriptions reported in the literature.[21]    
We identified potentially life threatening and immune mediated reactions in our dataset through 
a series of allergy/immunology specialist consultations and relevant literature sources [7, 9, 10]. 
Although our approach to classifying reactions without evaluating detailed lab/pathology 
information has its limitations, only slightly more than one-third of the reactions were potentially 
immune mediated (i.e. IgE mediated or T-cell mediated reactions such as anaphylaxis or rash) 
and one-tenth of the reactions were potentially life threatening (i.e. anaphylaxis or angioedema). 
Also, only about one-tenth of the alerts were based on the definite match between the allergy and 
prescribed medication, while the rest were based on either the cross-sensitivity or allergy group. 
In practice, these findings suggest that the majority of the drug allergy alerts present adverse 
sensitivity or side effect information to a related medication rather than true immune mediated 
reactions for the medication prescribed. These findings are similar to the previously reported 
trends.[13, 14]  
Our findings indicate an alarming trend of increasing drug allergy alert overrides over the last 10 
years. Two previous studies from one of the institutions in this study (Brigham and Women’s 
Hospital, which introduced one of the first computerized provider order entry systems over two 
decades ago) have shown that override rates increased from about 50% in 1995[13] to about 80% 
in 2002,[14] culminating in 86.3% in this study. This might suggest a general trend of increasing 
alert fatigue; providers are overwhelmed with frequent interruptive alerts and pay increasingly 
less attention to new alerts over time.[3, 4]  Recent studies from other sites have also identified 
similar or higher drug allergy alert override rates. For example, in their study of 643 alerts 
Hunteman et al. found that the overall drug allergy alert override rate was 97% and alerts were 
overridden with a frequency of 89% in a study of 2,676 opiate drug allergy alerts.[15]  
Drug class and reaction characteristics associated with provider’s tendency to override 
drug allergy alerts  
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Exploring factors affecting drug allergy alert override rates, we found that alerts based on the 
definite match between allergy and prescribed medication were overridden significantly less 
frequently than non-definite type matches. Similarly, alerts with potentially immune mediated 
and life threatening reactions were overridden less than others. Interestingly, there was only 
minute difference (of about 3%) between overrides of potentially life threatening vs. non-life 
threatening reactions. Providers were least likely to override alerts triggered by definite match 
for either potentially immune mediated or life threatening reactions. Although the general alert 
override rates were high for either type of reactions, our findings confirm the findings of the 
previous studies[14, 22] and indicate that providers pay attention to the nature of the reaction and 
type of match between the prescribed medication and allergy. Those results also underline a 
critical need for further investigation - potentially using qualitative methods- to better understand 
providers’ reasons to override even the most alarming drug allergy alerts. 
Providers were more likely to override drug allergy alerts for certain medication groups more 
frequently than others. For example, narcotic analgesic and statin alerts were overridden in 9 out 
of 10 cases. Salicylate analgesic (aspirin) and penicillin alerts were among the least overridden. 
This might be because both of those medication groups are frequently associated with more 
severe reactions (i.e. NSAIDs are commonly associated with angioedema, and penicillins with 
anaphylaxis) than other medications.[7] Consistent with the previous literature on the topic,[14] 
these results suggest that future drug allergy alerts can be presented differently (i.e. non 
interruptive vs. interruptive manner) for different medication groups to decrease the alert fatigue.  
Drug allergy alerts override reasons  
We found that more than half of the alerts were triggered for medications that patients have 
either previously tolerated or had no allergy to and each alert was fired more than twice after its 
first appearance. These results are similar to Hunteman et al. study findings indicating that 49% 
of overrides are for medications previously tolerated by patients. [15] In addition, providers were 
significantly more likely to override repeated alerts that were triggered twice or more times 
rather than first time alerts. This indicates that providers were overriding repeated alerts rather 
than removing the allergy from patients’ allergies lists in the electronic health records. Also, 
about one-third of the override reasons were classified as ‘others’, including single letters and 
other ambiguous entries. These entries are likely to be indicative of providers trying to save time 
and “click-out” of the time consuming tasks, such as providing free text alert override.    
In order to improve the quality and safety of patient care, providers should be encouraged to 
update the allergy list of their patients, which includes the removal of inaccurate allergies. In 
fact, our outpatient electronic health record system allergy module prompts providers to remove 
previously tolerated allergies from patient’s allergy list and similar practices should be applied in 
other settings/systems. However, based on the anecdotal evidence from our health system’s 
physicians, inpatient drug allergy alerting systems might need to differ from the outpatient 
systems. For example, several inpatient physicians suggested that they did not feel that they 
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knew their patients well enough to be able to remove allergies from the list and felt that this 
should be done by their primary care physicians. Our team is currently involved in a qualitative 
study of alert overrides that is likely shed light on these questions.            
Clearly, computerized provider order entry systems user interfaces must evolve to identify 
medications patients have no allergy to or tolerated in the past so providers are not inundated 
with highly irrelevant alerts.[2] Alerts to previously tolerated medications might be presented in 
a non-interruptive fashion (e.g., warning). Future systems should pay more attention to storage of 
override reason data while potentially triggering and encouraging providers to provide accurate 
override reasons.  
Solutions to high drug allergy alert override rates may be informed by drawing on our previous 
experiences with drug-drug interaction tiering. For example, our health system was one of the 
first to develop and implement a comprehensive approach to differentiating drug–drug 
interaction alerts by level of severity, also called “alert tiering”. Each drug-drug interaction alert 
was classified as: a) Level 1 alert - considered to be life threatening and the clinician is required 
either to cancel the order he or she is writing or discontinue the pre-existing drug order (a “hard 
stop”); b) Level 2 alert - less serious, but still requires action by the clinician in that the clinician 
is required to discontinue one or the other drug, or to select an override reason; and c) Level 3 
alert - least serious alerts and are informative only, requiring no action from the clinician.[23] 
This tiering approach was shown to decrease the drug-drug interaction alert override rates 
dramatically (e.g., 0% overrides at tiered hospital vs 66% at non-tiered hospital for severe alerts 
and  71% vs 90% for moderate alerts, respectively).[24]  
However, the tiering solutions developed so far have only limited applicability to the allergy 
domain. For example, level 1 “hard-stop” alerts may not be applicable to allergy because some 
patients can undergo drug desensitization that will potentially allow them to take the medications 
they were once allergic to. Also, severity of the drug allergy alert should be based on the patient 
reaction: life-threatening reactions (e.g, anaphylaxis or angioedema) should likely trigger 
interruptive alerts (level 2) while other less severe non-immune mediated reactions (e.g., nausea 
or myalgia) should trigger non-interruptive alerts (level 3). Further research is critically needed 
to better understand and develop a tiering structure for drug allergy alerts in addition to 
educating providers on the intricacies of accurate documentation of allergies and adverse 
sensitivities in EHRs.[25, 26]  
Limitations 
This study has several limitations. First, although we analyzed the largest dataset of drug allergy 
alerts reported so far, our data was limited to two large academic hospitals in Boston, which 
limits the generalizability of our findings. In addition, although based on the literature and expert 
panel discussions, our classification of potentially life threatening and potentially immune 
mediated reaction is an estimation based on the captured patient reactions rather than a 
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conclusive statement based on patient lab/ pathology or allergy tests. Also, drug allergy alert 
override reasons were available from only one of the study sites, which somewhat limits our 
inference for this data. Lastly, due to the large size of our dataset, we did not perform chart 
review on the patients whose drug allergy alerts were overridden to draw definitive conclusions 
about safety of current override practices.  
CONCLUSIONS 
This study examined one of the largest reported allergy datasets for trends in the most commonly 
triggered drug allergy alerts in inpatient settings. The most common drug allergy alerts were 
triggered by allergies to narcotics (almost half of the alerts) and other analgesics, several 
antibiotic groups, and statins. Only slightly more than one-third of the reactions were potentially 
immune mediated. Over the past decade, we identified an alarming trend of constantly increasing 
rate of drug allergy alert overrides, culminating in 87.6% in 2013. The drug allergy alert override 
rates were high for both potentially immune mediated or life threatening reactions. Overall, 
definite allergy and prescribed medication matches were overridden less frequently compared to 
probable or possible matches. The most overridden medication groups were the narcotic 
analgesics and statins. Finally, more than half of the overrides reasons pointed to irrelevant alerts 
(i.e. Patient has tolerated the medication before) and providers were significantly more likely to 
override repeated alerts rather than first time alerts. Our findings underline the urgent need for 
more efforts focused on providing more accurate and relevant drug allergy alerts for providers to 
decrease alert overrides and alert fatigue. Finally, further investigation is needed into providers’ 
reasons for overriding drug allergy alerts. 
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